Epigenetic liquid biopsies: a novel putative biomarker in immunology and inflammation

Trends Immunol. 2023 May;44(5):356-364. doi: 10.1016/j.it.2023.03.005. Epub 2023 Apr 1.

Abstract

Immune and inflammatory processes occurring within tissues are often undetectable by blood cell counts, standard circulating biomarkers, or imaging, representing an unmet biomedical need. Here, we outline recent advances indicating that liquid biopsies can broadly inform human immune system dynamics. Nucleosome-size fragments of cell-free DNA (cfDNA) released from dying cells into blood contain rich epigenetic information such as methylation, fragmentation, and histone mark patterns. This information allows to infer the cfDNA cell of origin, as well as pre-cell death gene expression patterns. We propose that the analysis of epigenetic features of immune cell-derived cfDNA can shed light on immune cell turnover dynamics in healthy people, and inform the study and diagnosis of cancer, local inflammation, infectious or autoimmune diseases, as well as responses to vaccination.

Keywords: DNA methylation; cell-free DNA; epigenetics; immune cell death; liquid biopsy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Cell-Free Nucleic Acids* / genetics
  • DNA Methylation*
  • Epigenesis, Genetic
  • Humans
  • Inflammation / genetics
  • Liquid Biopsy / methods

Substances

  • Biomarkers
  • Cell-Free Nucleic Acids